References in periodicals archive ?
Zidovudine-induced reversible pure red cell aplasia.
The pathogenesis of suspected pure red cell aplasia involves several mechanisms: immunoglobulins directed against erythropoietin or the cells themselves; T-cell cytokines blocking response to erythropoietin, particularly in chronic lymphocytic leukemia-related aplasia; and direct lysis of erythroid cells by a virus.
Evaluation of a patient with suspected pure red cell aplasia involves first stopping all medications that the patient is taking and then obtaining a bone marrow biopsy to confirm the diagnosis.
Marwaha RK, Bansal D, Trehan A, Marwaha N, Varma N: Clinico-haematological profile of pure red cell aplasia in children.
Pure red cell aplasia associated with parvovirus B19 infection occurring late after allogeneic bone marrow transplantation.
ASN Abstract #SU-FC061: Treatment of Erythropoietin Antibody-Mediated Pure Red Cell Aplasia with a Novel Synthetic Peptide-based Erythropoietin Receptor Agonist.
Pure red cell aplasia of long duration complicating major ABO-incompatible bone marrow transplantation.
The most serious adverse reactions in clinical studies were pulmonary embolism (PE) in one subject with a history of PE (in CIDP), an exacerbation of autoimmune pure red cell aplasia in one subject (in PI), and myocarditis in one subject that occurred 50 days post-study drug infusion and was not considered drug related (in ITP).
Cases of pure red cell aplasia (PRCA) and of severe anemia, with or without other cytopenias associated with neutralizing antibodies to erythropoietin have been reported in patients treated with Aranesp.
The most serious adverse reactions were pulmonary embolism (PE) in one subject with a history of PE (in CIDP), an exacerbation of autoimmune pure red cell aplasia in one subject (in PI), and myocarditis in one subject that occurred 50 days post-study drug infusion and was not considered drug related (in ITP).
Cases of pure red cell aplasia (PRCA) and of severe anemia, with or without other cytopenias, associated with neutralizing antibodies to erythropoietin have been reported in patients treated with PROCRIT predominantly in patients with chronic renal failure receiving PROCRIT by subcutaneous administration.
Cases of pure red cell aplasia (PRCA) and of severe anemia, with or without other cytopenias, associated with neutralizing antibodies to erythropoietin have been reported in patients treated with PROCRIT; predominantly in patients with chronic renal failure receiving PROCRIT by subcutaneous administration.